(2S,3R)-N-tert-butyloxycarbonyl-3-(tert-butyldimethylsilyloxy)-2-pyrrolidinecarboxylic acid methyl ester | 184046-77-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S,3R)-N-tert-butyloxycarbonyl-3-(tert-butyldimethylsilyloxy)-2-pyrrolidinecarboxylic acid methyl ester
• 英文别名: (2S,3R)-3-(tert-butyldimethylsilanyloxy)pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-methyl ester；1-O-tert-butyl 2-O-methyl (2S,3R)-3-[tert-butyl(dimethyl)silyl]oxypyrrolidine-1,2-dicarboxylate
• CAS: 184046-77-3
• 化学式: C₁₇H₃₃NO₅Si
• 分子量: 359.538
• InChiKey: OKKYDRPOCGYGKQ-OLZOCXBDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.56
• 重原子数：
  24
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  65.1
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (2S,3R)-N-tert-butyloxycarbonyl-3-(tert-butyldimethylsilyloxy)-2-pyrrolidinecarboxylic acid methyl ester 在 四丙基高钌酸铵 三乙基硼氢化锂 、 N-甲基吗啉氧化物 、 cesium fluoride 作用下， 以 四氢呋喃 、 二氯甲烷 、 乙腈 为溶剂， 反应 33.0h， 生成 (2R,3R)-3-(tert-butyldimethylsilanyloxy)-2-[(1S)-(2,2,2-trifluoro-1-hydroxyethyl)]-pyrrolidine-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  Discovery of Potent and Muscle Selective Androgen Receptor Modulators through Scaffold Modifications

  摘要：

  A novel series of imidazolin-2-ones were designed and synthesized as highly potent, orally active and muscle selective androgen receptor modulators (SARMs), with most of the compounds exhibiting low nM in vitro potency in androgen receptor (AR) binding and functional assays. Once daily oral treatment with the lead compound 11a (AR K-i = 0.9 nM, EC50 = 1.8 nM) for 14 days induced muscle growth with an ED50 of 0.09 mg/kg, providing approximately 50-fold selectivity over prostate growth in an orchidectomized rat model. Pharmacokinetic studies in rats demonstrated that the lead compound 11a had oral bioavailability of 65% and a plasma half-life of 5.5 h. On the basis of their preclinical profiles, the SARMs in this series are expected to provide beneficial anabolic effects on muscle with minimal androgenic effects on prostate tissue.

  DOI：

  10.1021/jm070312d
• 作为产物：
  描述：

  (2S,3R)-N-叔丁氧羰基-3-苯甲酰氧基-2-吡咯烷甲酸甲酯 在 4-二甲氨基吡啶 氢氧化钾 、 N,N-二异丙基乙胺 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 50.42h， 生成 (2S,3R)-N-tert-butyloxycarbonyl-3-(tert-butyldimethylsilyloxy)-2-pyrrolidinecarboxylic acid methyl ester
  参考文献：
  名称：

  Discovery of Potent and Muscle Selective Androgen Receptor Modulators through Scaffold Modifications

  摘要：

  A novel series of imidazolin-2-ones were designed and synthesized as highly potent, orally active and muscle selective androgen receptor modulators (SARMs), with most of the compounds exhibiting low nM in vitro potency in androgen receptor (AR) binding and functional assays. Once daily oral treatment with the lead compound 11a (AR K-i = 0.9 nM, EC50 = 1.8 nM) for 14 days induced muscle growth with an ED50 of 0.09 mg/kg, providing approximately 50-fold selectivity over prostate growth in an orchidectomized rat model. Pharmacokinetic studies in rats demonstrated that the lead compound 11a had oral bioavailability of 65% and a plasma half-life of 5.5 h. On the basis of their preclinical profiles, the SARMs in this series are expected to provide beneficial anabolic effects on muscle with minimal androgenic effects on prostate tissue.

  DOI：

  10.1021/jm070312d

文献信息

• Bicyclic modulators of androgen receptor function
  申请人：Nirschl Alexandra

  公开号：US20050197359A1

  公开（公告）日：2005-09-08

  The present invention relates to bicyclic compounds according to formula I, pharmaceutical compositions containing such compounds and methods of using such compounds in the treatment of androgen receptor-associated conditions, such as age-related diseases, for example sarcopenia, wherein R 1 , R 2 , R 5 , X, Y and n are defined herein.

  本发明涉及按照式I的双环化合物，包含这种化合物的药物组合物以及使用这种化合物治疗与雄激素受体相关疾病的方法，例如与年龄相关的疾病，例如肌少症，其中R1、R2、R5、X、Y和n在此处定义。
• Synthetic studies of the detoxin complex. I. total synthesis of (-) detoxinine
  作者：W.R. Ewing、B.D. Harris、K.L. Bhat、M.M. Joullie'

  DOI：10.1016/0040-4020(86)80005-9

  日期：1986.1

  A total synthesis of (-) detoxinine (1), the parent amino acid of the detoxin complex is reported. Two different routes to key intermediate 8a were developed: one from an acyclic precursor and the other from L-proline. The elaboration of 8a to 1 employed a stereoselective aldol condensation.

  据报道，共合成了排毒复合物的母体氨基酸（-）排毒素（1）。已开发出两种通往关键中间体8a的不同途径：一种途径来自无环前体，另一种途径来自L-脯氨酸。对8a至1的修饰采用了立体选择性醛醇缩合。
• 一种顺式-3-羟基-L-脯氨酸的制备方法
  申请人：武汉恒和达生物医药有限公司

  公开号：CN109232351A

  公开（公告）日：2019-01-18

  本发明提供了一种顺式‑3‑羟基‑L‑脯氨酸的制备方法，采用工业化生产的L‑丝氨酸为起始原料，通过邻位手性诱导的格式试剂对醛的亲核加成反应引入第二个手性中心，然后通过柱分离的方法将产品与异构体分离；再通过羟基的保护、硼氢化‑氧化反应构建了碳数与目标产物相同的中间体，再通过分子内的环化反应构建脯氨酸的五元环，进而脱除保护基，得到顺式‑3‑羟基‑L‑脯氨酸。该制备方法得到的产品化学纯度和光学纯度高，整个工艺简单易行，成本低廉，没有昂贵或者剧毒的原料或者试剂，适合公斤级的生产，具有较大的实施价值和社会经济效益。
• BICYCLIC MODULATORS OF ANDROGEN RECEPTOR FUNCTION
  申请人：Sun Chong-Qing

  公开号：US20080108649A1

  公开（公告）日：2008-05-08

  There are provided compounds according to formula I wherein the substitutents are as described herein. Further provided are methods of using such compounds for the treatment of nuclear hormone receptor-associated conditions, such as age related diseases, for example sarcopenia. Also provided are pharmaceutical compositions containing such compounds and processes for preparing some of the compounds of the invention. Other embodiments are also disclosed.

  提供了按公式I描述的化合物，其中取代基如此描述。还提供了使用这种化合物治疗核激素受体相关疾病的方法，例如与年龄相关的疾病，例如肌肉萎缩症。还提供了含有这种化合物的药物组合物和制备本发明部分化合物的方法。还揭示了其他实施例。
• Discovery of Potent and Muscle Selective Androgen Receptor Modulators through Scaffold Modifications
  作者：James J. Li、James C. Sutton、Alexandra Nirschl、Yan Zou、Haixia Wang、Chongqing Sun、Zulan Pi、Rebecca Johnson、Stanley R. Krystek,、Ramakrishna Seethala、Rajasree Golla、Paul G. Sleph、Blake C. Beehler、Gary J. Grover、Aberra Fura、Viral P. Vyas、Cindy Y. Li、Jack Z. Gougoutas、Michael A. Galella、Robert Zahler、Jacek Ostrowski、Lawrence G. Hamann

  DOI：10.1021/jm070312d

  日期：2007.6.1

  A novel series of imidazolin-2-ones were designed and synthesized as highly potent, orally active and muscle selective androgen receptor modulators (SARMs), with most of the compounds exhibiting low nM in vitro potency in androgen receptor (AR) binding and functional assays. Once daily oral treatment with the lead compound 11a (AR K-i = 0.9 nM, EC50 = 1.8 nM) for 14 days induced muscle growth with an ED50 of 0.09 mg/kg, providing approximately 50-fold selectivity over prostate growth in an orchidectomized rat model. Pharmacokinetic studies in rats demonstrated that the lead compound 11a had oral bioavailability of 65% and a plasma half-life of 5.5 h. On the basis of their preclinical profiles, the SARMs in this series are expected to provide beneficial anabolic effects on muscle with minimal androgenic effects on prostate tissue.